{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:58:27Z","timestamp":1792839507810,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.heliyon.2024.e36883","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T23:27:53Z","timestamp":1725060473000},"page":"e36883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Burden of illness of non-hematopoietic stem cell transplant-related hepatic sinusoidal obstruction syndrome: A systematic review"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4162-2346","authenticated-orcid":false,"given":"Lin","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darsh","family":"Devani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malia","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1273-3264","authenticated-orcid":false,"given":"Vian","family":"Amber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Hanvesakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e36883_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3389\/fimmu.2020.00489","article-title":"Diagnosis and treatment of VOD\/SOS after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Bonifazi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e36883_bib2","series-title":"DiPiro's Pharmacotherapy: A Pathophysiologic Approach","article-title":"Hematopoietic cell transplantation","author":"Dimaggio","year":"2023"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36883_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36883_bib4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jtct.2023.01.017","article-title":"Post-transplantation sinusoidal obstruction syndrome in adult patients with B cell acute lymphoblastic leukemia treated with pretransplantation inotuzumab","volume":"29","author":"Agrawal","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36883_bib5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10428194.2020.1827247","article-title":"Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin","volume":"62","author":"Ladha","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e36883_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26519","article-title":"Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites","volume":"64","author":"Toksvang","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e36883_bib7","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/pbc.22202","article-title":"Veno-occlusive disease as a complication of preoperative chemotherapy for Wilms tumor: a clinico-pathological analysis","volume":"53","author":"Jagt","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36883_bib8","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41409-019-0705-z","article-title":"Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a position statement from an international expert group","volume":"55","author":"Mohty","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.heliyon.2024.e36883_bib9","series-title":"Harrison's Principles of Internal Medicine","article-title":"Hematopoietic cell transplantation","author":"Appelbaum","year":"2022"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e36883_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2022.100558","article-title":"Hepatic venous pressure gradient in sinusoidal obstruction syndrome: diagnostic value and link with histological lesions","volume":"4","author":"Gressens","year":"2022","journal-title":"JHEP Reports"},{"key":"10.1016\/j.heliyon.2024.e36883_bib11","doi-asserted-by":"crossref","unstructured":"McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors. https:\/\/doi.org\/10.1002\/hep.1840040121. Hepatology. 1984\/01\/01 1984;4(1):116-122. doi:https:\/\/doi.org\/10.1002\/hep.1840040121.","DOI":"10.1002\/hep.1840040121"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36883_bib12","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e36883_bib13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e36883_bib14","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT)","volume":"58","author":"Mohty","year":"2023","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36883_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation","volume":"53","author":"Corbacioglu","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.heliyon.2024.e36883_bib16","first-page":"105","article-title":"Defibrotide in the treatment of hepatic veno-occlusive disease","volume":"8","author":"Fulgenzi","year":"2016","journal-title":"Hepat Med"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36883_bib18","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.12558","article-title":"BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation","volume":"163","author":"Dignan","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36883_bib19","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/hep.510300514","article-title":"\"Silent\" presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection","volume":"30","author":"Sebagh","year":"1999","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36883_bib20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4103\/ijmpo.ijmpo_188_16","article-title":"Sinusoidal obstruction syndrome during treatment for Wilms' tumor: a life-threatening complication","volume":"38","author":"Totadri","year":"2017","journal-title":"Indian J. Med. Paediatr. Oncol."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e36883_bib21","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1245\/s10434-012-2438-8","article-title":"Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis","volume":"19","author":"Robinson","year":"2012","journal-title":"Ann. Surg Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36883_bib22","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ags3.12233","article-title":"Current topics in liver surgery","volume":"3","author":"Yamazaki","year":"2019","journal-title":"Ann Gastroenterol Surg"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36883_bib23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2169\/internalmedicine.56.7669","article-title":"Hepatic sinusoidal obstruction syndrome induced by non-transplant chemotherapy for non-hodgkin lymphoma","volume":"56","author":"Sakumura","year":"2017","journal-title":"Intern Med"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36883_bib24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/hep.30222","article-title":"Liver complications following treatment of hematologic malignancy with anti-CD22-calicheamicin (inotuzumab ozogamicin)","volume":"69","author":"McDonald","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36883_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1524-4733.2003.00242.x","article-title":"A checklist for retrospective database studies--report of the ISPOR Task Force on Retrospective Databases","volume":"6","author":"Motheral","year":"2003","journal-title":"Value Health"},{"key":"10.1016\/j.heliyon.2024.e36883_bib26","series-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses","author":"Wells","year":"2023"},{"key":"10.1016\/j.heliyon.2024.e36883_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e36883_bib28","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth."},{"key":"10.1016\/j.heliyon.2024.e36883_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/lt.26452","article-title":"Sinusoidal obstruction syndrome after liver transplantation: a multicenter observational study","author":"Caballero-Marcos","year":"2022","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36883_bib30","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1245\/s10434-020-08988-4","article-title":"The impact of modern chemotherapy and chemotherapy-associated liver injuries (CALI) on liver function: value of 99mTc-labelled-mebrofenin SPECT-hepatobiliary scintigraphy","volume":"28","author":"Truant","year":"2021","journal-title":"Ann. Surg Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36883_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00280-002-0546-z","article-title":"Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia","volume":"51","author":"Alvarado","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"14","key":"10.1016\/j.heliyon.2024.e36883_bib32","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1182\/blood-2009-07-230656","article-title":"Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial","volume":"115","author":"Stork","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e36883_bib33","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36883_bib34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2141.2003.04578.x","article-title":"Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia","volume":"123","author":"Stoneham","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e36883_bib35","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/lt.22282","article-title":"Significance of isolated hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after liver transplantation","volume":"17","author":"Sebagh","year":"2011","journal-title":"Liver Transpl"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36883_bib36","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41409-019-0690-2","article-title":"Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia","volume":"55","author":"Debureaux","year":"2020","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36883_bib37","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e36883_bib38","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1038\/s41375-021-01203-7","article-title":"Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia","volume":"35","author":"Stanulla","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2024.e36883_bib39","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7580642","article-title":"A retrospective cohort study of the efficacy, safety, and clinical value of 6-TG versus 6-MP maintenance therapy in children with acute lymphoblastic leukemia","volume":"2022","author":"Tu","year":"2022","journal-title":"BioMed Res. Int."},{"issue":"SUPPL 5","key":"10.1016\/j.heliyon.2024.e36883_bib40","article-title":"Hepatic sinusoidal obstruction syndrome post-chemotherapy in pediatric and adolescent age: case series of six patients in Qatar","volume":"68","author":"Alsaad","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"issue":"SUPPL 5","key":"10.1016\/j.heliyon.2024.e36883_bib41","article-title":"Veno-occlusive disease following non transplant-associated chemotherapy in Spain: a registry of the pediatric haematology and Oncology society","volume":"68","author":"Solano-Paez","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36883_bib42","doi-asserted-by":"crossref","first-page":"338 e1","DOI":"10.1016\/j.jtct.2020.11.016","article-title":"Sinusoidal obstruction syndrome in critically ill patients in the era of defibrotide: a retrospective multicenter study","volume":"27","author":"Debureaux","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36883_bib43","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2004-10-3821","article-title":"Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia","volume":"106","author":"Arceci","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36883_bib44","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12185-013-1275-2","article-title":"Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice","volume":"97","author":"Tallman","year":"2013","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36883_bib45","first-page":"36","article-title":"Use of gemtuzumab ozogamicin in the treatment of pediatric relapsed\/refractory acute myeloid leukemia","volume":"25","author":"Unal","year":"2008","journal-title":"Turkish Journal of Hematology"},{"issue":"9544","key":"10.1016\/j.heliyon.2024.e36883_bib46","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(06)69558-5","article-title":"Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial","volume":"368","author":"Vora","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36883_bib47","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/pbc.22841","article-title":"Veno-occlusive disease in pediatric patients affected by Wilms tumor","volume":"57","author":"Cesaro","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36883_bib48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36883_bib49","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00280-002-0539-y","article-title":"Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia","volume":"50","author":"Cortes","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"15","key":"10.1016\/j.heliyon.2024.e36883_bib50","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","article-title":"Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study","volume":"1","author":"DeAngelo","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36883_bib51","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000064700","article-title":"Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome","volume":"108","author":"Giles","year":"2002","journal-title":"Acta Haematol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e36883_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27269","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: final results from a post hoc analysis of data from an expanded-access program","volume":"65","author":"Kernan","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.heliyon.2024.e36883_bib53","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.leukres.2016.03.004","article-title":"Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry","volume":"44","author":"Magwood-Golston","year":"2016","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36883_bib54","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00280-017-3453-z","article-title":"Treatment-related sinusoidal obstruction syndrome in children with de novo acute lymphoblastic leukemia during intensification","volume":"80","author":"McAtee","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36883_bib55","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/cncr.11239","article-title":"Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e36883_bib56","first-page":"339","article-title":"The DEFIfrance registry study: effectiveness and safety of defibrotide in patients with veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS) following chemotherapy","volume":"57","author":"Yakoub-Agha","year":"2022","journal-title":"Bone Marrow Transplant."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e36883_bib57","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/imj.13550","article-title":"New insights into sinusoidal obstruction syndrome","volume":"47","author":"Piccin","year":"2017","journal-title":"Intern. Med. J."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e36883_bib58","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.bbmt.2016.07.001","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the international compassionate-use program","volume":"22","author":"Corbacioglu","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e36883_bib59","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1097\/MPH.0000000000000958","article-title":"Sinusoidal obstruction syndrome during chemotherapy of pediatric cancers and its successful management with defibrotide","volume":"39","author":"Kizilocak","year":"2017","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36883_bib60","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/bjh.17936","article-title":"Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia","volume":"196","author":"Egnell","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36883_bib61","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.surg.2021.05.034","article-title":"Validation of the IMM classification in laparoscopic repeat liver resections for colorectal liver metastases","volume":"170","author":"Hobeika","year":"2021","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36883_bib62","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ejso.2013.12.009","article-title":"Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome","volume":"40","author":"Imai","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36883_bib63","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/1440257","article-title":"Extracellular volume fraction calculated using contrast-enhanced computed tomography as a biomarker of oxaliplatin-induced sinusoidal obstruction syndrome: a preliminary histopathological analysis","volume":"2023","author":"Kai","year":"2023","journal-title":"Journal of oncology"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36883_bib64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00595-010-4414-x","article-title":"Sinusoidal obstruction syndrome compromises liver regeneration in patients undergoing two-stage hepatectomy with portal vein embolization","volume":"41","author":"Narita","year":"2011","journal-title":"Surg. Today"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36883_bib65","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12957-017-1290-5","article-title":"Changes of liver hemodynamic and elastography parameters in patients with colorectal liver metastases receiving preoperative chemotherapy: \"a note of caution\"","volume":"15","author":"Pelegrina","year":"2017","journal-title":"World J. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36883_bib66","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/SLA.0b013e3181c79403","article-title":"Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome","volume":"251","author":"Soubrane","year":"2010","journal-title":"Ann. Surg."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36883_bib67","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1245\/s10434-013-2915-8","article-title":"Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases","volume":"20","author":"van den Broek","year":"2013","journal-title":"Ann. Surg Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36883_bib68","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/bjc.2012.590","article-title":"Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer","volume":"108","author":"Vreuls","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e36883_bib69","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1007\/s00268-012-1565-5","article-title":"Prolonged portal triad clamping increases postoperative sepsis after major hepatectomy in patients with sinusoidal obstruction syndrome and\/or steatohepatitis","volume":"36","author":"Narita","year":"2012","journal-title":"World J. Surg."},{"key":"10.1016\/j.heliyon.2024.e36883_bib70","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejrad.2017.06.025","article-title":"Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: radio-pathological correlation","volume":"94","author":"Cayet","year":"2017","journal-title":"Eur. J. Radiol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e36883_bib71","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.ejso.2018.07.050","article-title":"Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): multicentric study of patients operated for colorectal liver metastases","volume":"44","author":"Hubert","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36883_bib72","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ejso.2016.02.017","article-title":"Sinusoidal dilation increases the risk of complications in hepatectomy for CRCLM - protective effect of bevacizumab and diabetes mellitus, serum gamma-glutamyltranspeptidase as predictive factor","volume":"42","author":"Martins","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36883_bib73","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1186\/s12885-020-07282-6","article-title":"Quantified MRI and 25OH-VitD3 can be used as effective biomarkers for patients with neoadjuvant chemotherapy-induced liver injury in CRCLM?","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e36883_bib74","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/hpb.12047","article-title":"Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab","volume":"15","author":"Hubert","year":"2013","journal-title":"HPB (Oxford)"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36883_bib75","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s11605-020-04636-0","article-title":"Does chemotherapy-induced liver injury impair postoperative outcomes after laparoscopic liver resection for colorectal metastases?","volume":"25","author":"Neuberg","year":"2021","journal-title":"J. Gastrointest. Surg."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e36883_bib76","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s12094-019-02245-1","article-title":"Splenic volume as a biomarker of hepatic damage after chemotherapy in patients with resected colorectal liver metastases (CRLM)","volume":"22","author":"Saez-Carlin","year":"2020","journal-title":"Clin. Transl. Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36883_bib77","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.surg.2020.04.015","article-title":"Relevance of blood loss as key indicator of the quality of surgical care in laparoscopic liver resection for colorectal liver metastases","volume":"168","author":"Nassar","year":"2020","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36883_bib78","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s00330-011-2333-x","article-title":"Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases","volume":"22","author":"Shin","year":"2012","journal-title":"Eur. Radiol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e36883_bib79","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1245\/s10434-011-2112-6","article-title":"Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization","volume":"19","author":"Narita","year":"2012","journal-title":"Ann. Surg Oncol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e36883_bib80","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.hpb.2022.08.003","article-title":"Radiological and pathological assessment with EOB-MRI after Y90 radiation lobectomy prior to liver resection for hepatocellular carcinoma","volume":"24","author":"Bekki","year":"2022","journal-title":"HPB"},{"key":"10.1016\/j.heliyon.2024.e36883_bib81","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2022.11.001","article-title":"Immune-related generalised oedema - a new category of adverse events with immune checkpoint inhibitors","volume":"179","author":"Velev","year":"2023","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36883_bib82","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13244-022-01281-w","article-title":"Multiparametric MRI with MR elastography findings in patients with sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy","volume":"13","author":"Poker","year":"2022","journal-title":"Insights into Imaging"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36883_bib83","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.transproceed.2014.02.021","article-title":"Chronic immune-mediated reaction syndrome as the cause of late graft mortality in living-donor liver transplantation for primary biliary cirrhosis","volume":"46","author":"Harimoto","year":"2014","journal-title":"Transplant. Proc."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36883_bib84","doi-asserted-by":"crossref","first-page":"214","DOI":"10.6002\/ect.2017.0315","article-title":"Long-Term outcome of veno-occlusive disease after liver transplant: a retrospective single-center experience","volume":"17","author":"Patrono","year":"2019","journal-title":"Exp Clin Transplant"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e36883_bib85","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1097\/TP.0b013e318234119d","article-title":"Acute cellular rejection resulting in sinusoidal obstruction syndrome and ascites postliver transplantation","volume":"92","author":"Sanei","year":"2011","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e36883_bib86","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/petr.12373","article-title":"Basiliximab treatment for steroid-resistant rejection in pediatric patients following liver transplantation for acute liver failure","volume":"18","author":"Shigeta","year":"2014","journal-title":"Pediatr. Transplant."},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e36883_bib87","article-title":"Clinical impact and treatment of veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS) after liver transplant (LT). The role of transjugular intrahepatic porto-systemic shunt (TIPS)","volume":"55","author":"Triolo","year":"2023","journal-title":"Dig. Liver Dis."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36883_bib88","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520926031","article-title":"Gd-EOB-DTPA-enhanced MR findings in chemotherapy-induced sinusoidal obstruction syndrome in colorectal liver metastases","volume":"48","author":"Ding","year":"2020","journal-title":"J. Int. Med. Res."},{"issue":"26","key":"10.1016\/j.heliyon.2024.e36883_bib89","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1200\/JCO.2008.16.1893","article-title":"Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases","volume":"26","author":"Ward","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"SUPPL 2","key":"10.1016\/j.heliyon.2024.e36883_bib90","first-page":"A129","article-title":"Hepatic sinusoidal obstruction syndrome in children treated for solid malignant tumors-diagnosis and treatment","volume":"106","author":"Giljevic","year":"2021","journal-title":"Arch. Dis. Child."},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e36883_bib91","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2021-152791","article-title":"FLT3-Mutated acute myeloid leukemia using a novel regimen of gemtuzumab ozogamicin and midostaurin in combination with standard cytarabine and daunorubicin induction therapy","volume":"138","author":"Borate","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.heliyon.2024.e36883_bib92","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1182\/blood-2003-05-1620","article-title":"A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia","volume":"102","author":"Kell","year":"2003","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e36883_bib93","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/1042819042000219485","article-title":"Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas","volume":"45","author":"Piccaluga","year":"2004","journal-title":"Leuk. Lymphoma"},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e36883_bib94","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-150069","article-title":"Gemtuzumab ozogamicin plus midostaurin in combination with standard intensive induction therapy in newly diagnosed AML: results from a phase-I study","volume":"138","author":"R\u00f6llig","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e36883_bib95","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.18203","article-title":"Single-dose (4.5 mg\/m(2) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia","author":"Dhunputh","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36883_bib96","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3324\/haematol.2018.191841","article-title":"Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Munster study group","volume":"104","author":"Niktoreh","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36883_bib97","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3324\/haematol.2016.141937","article-title":"Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg\/m2 with 6 mg\/m2 in the NCRI AML17 Trial","volume":"101","author":"Burnett","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e36883_bib98","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1080\/10428194.2020.1742897","article-title":"Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia","volume":"61","author":"Wang","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e36883_bib99","article-title":"Feasibility and safety of using gemtuzumab ozogamicin in the treatment of acute myeloid leukemia: real world data from a tertiary care cancer center in India","volume":"38","author":"Guntiboina","year":"2022","journal-title":"Indian Journal of Hematology and Blood Transfusion"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36883_bib100","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2017.2380","article-title":"Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial","volume":"4","author":"Jabbour","year":"2018","journal-title":"JAMA Oncol."},{"issue":"Supplement 5","key":"10.1016\/j.heliyon.2024.e36883_bib101","article-title":"Inotuzumab ozogamicin (INO) combined with chemotherapy in pediatric patients with relapsed\/refractory CD22+ B-cell precursor acute lympholastic leukemia (BCP-ALL) - results from the ITCC-059 1B trial","volume":"69","author":"Pennesi","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36883_bib102","first-page":"15","article-title":"Late retransplantation of the liver: a single-centre experience","volume":"58","author":"Adani","year":"2006","journal-title":"Chir. Ital."},{"key":"10.1016\/j.heliyon.2024.e36883_bib103","doi-asserted-by":"crossref","DOI":"10.1007\/s13304-022-01280-y","article-title":"Physiological reno-portal bypass in liver transplantation with non-tumorous portal vein thrombosis","author":"Pinelli","year":"2022","journal-title":"Updates Surg"},{"key":"10.1016\/j.heliyon.2024.e36883_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101557","article-title":"Prevalence and outcomes of patients with sinusoidal obstruction syndrome after liver transplantation: a ten year's experience of a single center in Japan","volume":"71","author":"Sanada","year":"2022","journal-title":"Transpl. Immunol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e36883_bib105","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27695","article-title":"PAI-1 and protein C as early markers of veno-occlusive disease in patients treated for Wilms tumor","volume":"66","author":"Cesaro","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36883_bib106","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27518","article-title":"Treatment of hepatic veno-occlusive disease in children with N-acetylcysteine","volume":"66","author":"Lee","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"issue":"Supplement 5","key":"10.1016\/j.heliyon.2024.e36883_bib107","first-page":"S235","article-title":"Age as a prognostic variable in children and adolescents with favourable histology (FH) Wilms tumour (WT)","volume":"69","author":"Panda","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e36883_bib108","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1007\/s10147-022-02235-4","article-title":"Usefulness of ultrasonography and elastography in diagnosing oxaliplatin-induced sinusoidal obstruction syndrome","volume":"27","author":"Saito","year":"2022","journal-title":"Int. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36883_bib109","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12885-016-2998-2","article-title":"Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis","volume":"17","author":"Stevenson","year":"2017","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36883_bib110","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2559.2012.04208.x","article-title":"Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases","volume":"61","author":"Vreuls","year":"2012","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36883_bib111","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/pbc.20964","article-title":"Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group\/National Cancer Institute pilot trial (CCG-1942)","volume":"49","author":"Jacobs","year":"2007","journal-title":"Pediatr. Blood Cancer"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36883_bib112","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/MPH.0000000000002281","article-title":"Abdominal complications during treatment for pediatric acute myeloid leukemia","volume":"44","author":"Borgstedt-Bendixen","year":"2022","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"Supplement 3","key":"10.1016\/j.heliyon.2024.e36883_bib113","first-page":"iii1","article-title":"AT-05. Veno-occlusive diease (VOD) is a notable side effect of therapy in infants with rhabdid tumors","volume":"18","author":"Seeringer","year":"2016","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36883_bib114","article-title":"A modified IRS-III chemotherapy regimen leads to prolonged survival in children with embryonal tumor with multilayer rosettes","volume":"2","author":"Hanson","year":"2020","journal-title":"Neurooncol Adv"},{"issue":"Supplement_3","key":"10.1016\/j.heliyon.2024.e36883_bib115","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaa222.499","article-title":"MBCL-23. Preliminary analysis of treatment-related toxicities during inducation chemotherapy for patients on the Head Start 4 trial","volume":"22","author":"Agarwal","year":"2020","journal-title":"Neuro Oncol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e36883_bib116","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/cncr.20928","article-title":"The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group","volume":"103","author":"Bisogno","year":"2005","journal-title":"Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e36883_bib117","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2020-135857","article-title":"Favorable outcomes in pediatric patients in the phase 3 hgb-207 (Northstar-2) and hgb-212 (Northstar-3) studies of betibeglogene autotemcel gene therapy for the treatment of transfusion-dependent \u03b2-thalassemia","volume":"136","author":"Thompson","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e36883_bib118","article-title":"Veno-occlusive disease\/sinusoidal obstruction syndrome without hematopoietic cell transplantation in a real-world population in the United States: patient characteristics, prior treatment patterns, and time to diagnosis","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e36883_bib119","article-title":"Long-term survival in patients undergoing trans jugular intrahepatic portosystemic shunt placement after liver transplantation","volume":"55","author":"Leonardi","year":"2023","journal-title":"Dig. Liver Dis."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36883_bib120","first-page":"373","article-title":"Transjugular Intrahepatic Portosystemic Shunt in Liver Transplant Recipients: Outcomes in Six Adult Patients. Vascular and Endovascular","volume":"57","author":"Masek","year":"2023","journal-title":"Surgery"},{"issue":"SUPPL 2","key":"10.1016\/j.heliyon.2024.e36883_bib121","first-page":"628","article-title":"EP1301. Interim results of betibeglogene autotemcel gene therapy in pediatric patients with transfusion-dependent beta-thalassemia (TDT) treated in the phase 3 Northstar-2 and Northstar-3 studies","volume":"5","author":"Kulozik","year":"2021","journal-title":"HemaSphere"},{"key":"10.1016\/j.heliyon.2024.e36883_bib122","article-title":"Clinical benefits and safety of gemtuzumab ozogamicin in treating acute myeloid leukemia in various subgroups: an updated systematic review, meta-analysis, and network meta-analysis","volume":"12","author":"Xu","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36883_bib123","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212157","article-title":"Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: a systematic review","volume":"14","author":"Toksvang","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e36883_bib124","first-page":"P135","article-title":"Defibrotide for treatment of adults with hepatic VOD\/SOS with or without multiorgan failure after hematopoietic cell transplantation: results of a systematic review\/meta-analysis","volume":"54","author":"Kharfan-Dabaja","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36883_bib125","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjh.15267","article-title":"Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"181","author":"Kernan","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e36883_bib126","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1055\/s-0039-1698763","article-title":"Efficacy and safety of defibrotide for the treatment of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"45","author":"Yang","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e36883_bib127","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41409-022-01900-6","article-title":"Real-world use of defibrotide for veno-occlusive disease\/sinusoidal obstruction syndrome: the DEFIFrance Registry Study","volume":"58","author":"Mohty","year":"2023","journal-title":"Bone Marrow Transplant."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e36883_bib128","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s41409-019-0474-8","article-title":"Systematic review of defibrotide studies in the treatment of veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS)","volume":"54","author":"Richardson","year":"2019","journal-title":"Bone Marrow Transplant."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024129143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024129143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T10:17:42Z","timestamp":1775729862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024129143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":127,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2405844024129143"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36883","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burden of illness of non-hematopoietic stem cell transplant-related hepatic sinusoidal obstruction syndrome: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e36883"}}